STALICLA
23.8.2019 02:02:11 CEST | Business Wire | Press release
STALICLA, a Swiss Biotech company, today announced the completion of its pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) on the preparation for entry of STP1 into clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005559/en/
“We are appreciative of FDA´s technical guidance and strong interest in personalized medicine approaches for patients with Autism Spectrum Disorder. STALICLA is committed to rapidly move forward with the submission of its STP1 IND. STP1 holds the potential to become the first precision medicine for a subgroup of patients with ASD, and herald a new age for this field.”
- Lynn Durham, CEO and Founder of STALICLA.
ASD is a common neurodevelopmental disorder, with high level of heterogeneity, that affects 1 in 59 8-year-old school children in the U.S. (CDC, 2018 ). Eighty percent of patients are still considered idiopathic (without a genetically identifiable cause). Traditionally, drug developers have approached ASD as a single-disease entity, overlooking its clinical complexity and biological heterogeneity.
STP1 has been developed using STALICLA´s innovative systems biology-driven platform (DEPI), which is an integrative framework that uses large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups in ASD and to identify personalized treatments.
This is the first time that such technologies have been utilized within the field of neurodevelopment, and it is a hugely exciting project with scope to change the direction of this speciality.
STALICLA will submit its STP1 IND to enter a Phase 1b clinical trial. |
The First ‘Phenotype 1’ ASD patients will be enrolled in early 2020. |
About STALICLA
STALICLA is a near clinical Swiss Biotech Company developing a unique approach to bring personalized medicine to patients with ASD. Today, patients with ASD account for approximately 1.5% of the world’s population, and the condition remains a high unmet medical need.
In its Geneva and Barcelona units, STALICLA has assembled world-class teams of experienced drug developers and computational biologists. The Company is recognized as a disruptive player, using its systems biology DEPI platform to identify subgroups of patients with ASD and candidate repurposed and rescued drugs. Patients are then characterized through biomarker preclinical and clinical investigations. This translates into a derisked drug development process bringing the vision of ASD personalized medicine to reality.
STALICLA’s first investigational precision medicine - STP1 - addresses a distinct subgroup of ASD patients estimated to 2 million people in Europe and North America. To support STP1’s development and create strong value for all stakeholders, STALICLA has developed a network of top-tier research and clinical partners and established IP as a strategic priority. STALICLA is currently applying its DEPI discovery model to characterize additional subgroups of patients and advance new pipelines. Applicability of the DEPI platform goes beyond ASD and has potential for drug discovery in other complex ill-defined diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190822005559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Apis Partners Announces Final Close of $1.23 Billion Fund III, Double its Predecessor7.5.2026 08:00:00 CEST | Press release
Fund III closes 23% above target, more than double Fund II Around 50% of capital raised from existing LPs increasing commitments Fund III to invest in tech-enabled financial infrastructure and services companies across Europe and growth markets Apis Partners Group (UK) Limited (“Apis”), a private equity firm investing in tech-enabled businesses in financial infrastructure and services, today announced the final close of Apis Global Growth Fund III and Apis Growth Markets Fund III (the “Funds” or “Fund III”), with combined commitments of $1.23 billion excluding co-investments, more than double its predecessor, Apis Growth Fund II, at $563 million. The Funds closed 23% above target.Reflecting the strong performance of previous funds,which have already generated in excess of $1 billion in realisations to date, over 70% of existing LPs have re-upped and increased on their previous fund’s commitments, accounting for around 50% of the total capital raised in Fund III. The significant increas
Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 20267.5.2026 07:13:00 CEST | Press release
A path breaking scientific discovery, unraveling successful wound healing mechanism in urethral stricture with BEES-HAUS cell therapy has been reported by Indo-Japan physician-scientists. This milestone achievement in regenerative medicine, yielding clinical safety and efficacy, is the first of its kind, wherein a hybrid approach of mixing two groups of autologous buccal epithelial cells,one cultured in 2D and another in 3D in Festigel scaffold were used in the management of urethral stricture; paracrine effect of IGF-1 produced by 2D-cultured cells and engraftment of 3D-Festigel cultured cells, which cover the urethrotomy wound, together repairing the urothelial defect, has been published in Frontiers in Urology. This feat though modest, is a global first in terms of both in vitro tissue engineering and clinical benefits by in vivo healing, restoring the urothelial integrity and is a giant leap for its potential of yielding stricture recurrence-free good quality of life to patients wi
Interactive Brokers Launches Access to Korean Equities, Breaking New Ground for Global Investors7.5.2026 03:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of access to equities listed on the Korea Exchange (KRX), becoming the first major US-based broker to offer seamless trading in Korea's $1.8 trillion equity market. Korea ranks fourth among Asia's equity markets and tenth globally by market capitalization, with over $10 billion in daily volume – liquidity comparable to many European exchanges. The market is home to category-leading semiconductor manufacturers, automotive innovators, and consumer technology companies with global footprints, including Samsung Electronics, SK Hynix, and Hyundai Motor. As one of Asia’s most liquid markets, Korea represents a point of entry for international investors seeking exposure to the region’s technology leadership and industrial innovation. For investors operating across multiple markets and time zones, Interactive Brokers' launch expands the ability to build truly global portfolios with the same integrated tr
Andersen Global udvider med samarbejdspartneren NetExpat7.5.2026 01:38:00 CEST | Pressemeddelelse
Andersen Global styrker sin platform på tværs af Asien-Stillehavsområdet, Europa og USA gennem en samarbejdsaftale med NetExpat, der er en virksomhed med speciale i medarbejderassistance, interkulturel oplæring og ledelsesudvikling for internationalt mobile medarbejdere. NetExpat blev grundlagt for mere end 25 år siden og er en anerkendt markedsleder inden for global mobilitet og talentudvikling med støtte til multinationale kunder verden over. Virksomheden tilbyder vurderings-, trænings- og coachingprogrammer, der er designet til at understøtte globale arbejdsstyrker og deres medarbejdere i forbindelse med flytninger, herunder interkulturelle parathedsvurderinger, målrettet, effektiv kulturoplæring, karriere- og integrationsstøtte til medarbejderes ægtefæller samt talentudviklingsprogrammer for internationalt orienterede teams. "I mere end to årtier har NetExpat haft fokus på at hjælpe organisationer og deres medarbejdere med at trives med international mobilitet," udtaler Alain Verst
Brightfin Launches Spend Clearly AI to Help Enterprise Tech Leaders Take Control of Growing IT and AI Costs6.5.2026 22:32:00 CEST | Press release
New AI-powered optimization app delivers real-time visibility, cost reduction, and predictive forecasting as enterprise AI spending accelerates Brightfin, a leader in AI native IT cost optimization, today announced the launch of Spend Clearly AI, an intelligent optimization app purpose-built for enterprise technology leaders navigating the dual pressures of rising IT complexity and rapidly escalating AI investment. As organizations race to deploy AI apps, models, and infrastructure, technology demands on the budget are expanding faster than ever and growing harder to track, justify, and control. The modern enterprise IT bill has become a moving target. Spend Clearly AI gives CIOs, CTOs, and IT finance teams a single, intelligent app to see exactly where every technology dollar is going, eliminate waste, and stay ahead of costs before they spiral. "Stop thinking about IT as a cost problem. The goal isn't just to spend less — the goal is to spend better," said Joel Martins, CEO of Bright
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom